Andrews Lily J, Davies Philippa, Herbert Christopher, Kurian Kathreena M
Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Front Oncol. 2023 May 17;13:1163289. doi: 10.3389/fonc.2023.1163289. eCollection 2023.
Glioma is one of the most common malignant primary brain tumours in adults, of which, glioblastoma is the most prevalent and malignant entity. Glioma is often diagnosed at a later stage of disease progression, which means it is associated with significant mortality and morbidity. Therefore, there is a need for earlier diagnosis of these tumours, which would require sensitive and specific biomarkers. These biomarkers could better predict glioma onset to improve diagnosis and therapeutic options for patients. While liquid biopsies could provide a cheap and non-invasive test to improve the earlier detection of glioma, there is little known on pre-diagnostic biomarkers which predate disease detection. In this review, we examine the evidence in the literature for pre-diagnostic biomarkers in glioma, including metabolomics and proteomics. We also consider the limitations of these approaches and future research directions of pre-diagnostic biomarkers for glioma.
神经胶质瘤是成人中最常见的原发性恶性脑肿瘤之一,其中胶质母细胞瘤是最普遍且恶性程度最高的类型。神经胶质瘤往往在疾病进展的后期才被诊断出来,这意味着它与较高的死亡率和发病率相关。因此,需要对这些肿瘤进行早期诊断,而这需要敏感且特异的生物标志物。这些生物标志物能够更好地预测神经胶质瘤的发病,从而改善患者的诊断和治疗选择。虽然液体活检可以提供一种廉价且非侵入性的检测方法来提高神经胶质瘤的早期检测率,但对于在疾病检测之前的诊断前生物标志物却知之甚少。在这篇综述中,我们研究了文献中关于神经胶质瘤诊断前生物标志物的证据,包括代谢组学和蛋白质组学。我们还考虑了这些方法的局限性以及神经胶质瘤诊断前生物标志物的未来研究方向。